Profile - To The Moon

KkKkkkk

Posts · 86Posts · 86
Following · 0Following · 0
Followers · 0Followers · 0

- KkKkkkkKkKkkkk
  ·2022-02-17
  👍👍👍👍👍
  After-Hours Stock Movers: Cisco,DoorDash,Fastly,AppLovin,Matterport and More
  After-Hours Stock Movers:DoorDash (NYSE:DASH)27.1% HIGHER; reported Q4 EPS of ($0.45), $0.18 worse t
  After-Hours Stock Movers: Cisco,DoorDash,Fastly,AppLovin,Matterport and More
  481 Comment
  4
  Share
  Report
- KkKkkkkKkKkkkk
  ·2022-02-13
  👍👍👍👍👍
  China Approves Use of Pfizer's COVID Drug Paxlovid
  BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditi
  China Approves Use of Pfizer's COVID Drug Paxlovid
  421 Comment
  3
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-23
  ??????
  106 Comment
  1
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-22
  ?????
  284 Comment
  Like
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-21
  ?????
  148 Comment
  1
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-20
  ?????
  120 Comment
  Like
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-13
  ??????
  286 Comment
  1
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-12
  ?????
  162 Comment
  1
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-11
  ????
  202 Comment
  1
  Share
  Report
- KkKkkkkKkKkkkk
  ·2021-09-10
  ????
  210 Comment
  1
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586770547015924","uuid":"3586770547015924","gmtCreate":1623676523611,"gmtModify":1623676523611,"name":"KkKkkkk","pinyin":"kkkkkkk","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":26,"tweetSize":86,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9094951902,"gmtCreate":1645054470282,"gmtModify":1676533990933,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"👍👍👍👍👍","listText":"👍👍👍👍👍","text":"👍👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094951902","repostId":"1161878158","repostType":4,"repost":{"id":"1161878158","pubTimestamp":1645053544,"share":"https://ttm.financial/m/news/1161878158?lang=&edition=fundamental","pubTime":"2022-02-17 07:19","market":"us","language":"en","title":"After-Hours Stock Movers: Cisco,DoorDash,Fastly,AppLovin,Matterport and More","url":"https://stock-news.laohu8.com/highlight/detail?id=1161878158","media":"StreetInsider","summary":"After-Hours Stock Movers:DoorDash (NYSE:DASH)27.1% HIGHER; reported Q4 EPS of ($0.45), $0.18 worse t","content":"<html><head></head><body><p>After-Hours Stock Movers:</p><p>DoorDash (NYSE:DASH)27.1% HIGHER; reported Q4 EPS of ($0.45), $0.18 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.28 billion. We expect Q1 Marketplace GOV to be in a range of $11.4 billion to $11.8 billion, with Q1 Adjusted EBITDA in a range of $0 million to $50 million. We expect 2022 Marketplace GOV to be in a range of $48 billion to $50 billion, with 2022 Adjusted EBITDA in a range of $0 million to $500 million.</p><p>Fastly, Inc. (NYSE:FSLY)23.3% LOWER; reported Q4 EPS of ($0.10), $0.06 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $97.7 million versus the consensus estimate of $92.44 million. Fastly, Inc. sees Q1 2022 EPS of ($0.15)-($0.13), versus the consensus of ($0.13). Fastly, Inc. sees Q1 2022 revenue of $97-100 million, versus the consensus of $97.98 million. Fastly, Inc. sees FY2022 EPS of ($0.60)-($0.50), versus the consensus of ($0.48). Fastly, Inc. sees FY2022 revenue of $400-410 million, versus the consensus of $418.98 million.</p><p>10x Genomics (NASDAQ:TXG)21.3% LOWER; reported Q4 EPS of ($0.16), $0.07 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $143.5 million versus the consensus estimate of $148.53 million. 10x Genomics sees FY2022 revenue of $600-630 million, versus the consensus of $679 million.</p><p>AppLovin (NASDAQ:APP)17% LOWER; reported Q4 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $793 million versus the consensus estimate of $783.36 million. AppLovin sees FY2022 revenue of $3.55-3.85 billion, versus the consensus of $3.82 billion.</p><p>Matterport, Inc. (NASDAQ:MTTR)10.1% LOWER; reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $27.1 million versus the consensus estimate of $25.13 million. Total subscribers increased 98% to 503,000 from year-ago period. Matterport, Inc. sees Q1 2022 EPS of ($0.13)-($0.15), versus the consensus of ($0.04). Matterport, Inc. sees Q1 2022 revenue of $25.5-27.5 million, versus the consensus of $31.85 million. Matterport, Inc. sees FY2022 EPS of ($0.47)-($0.52), versus the consensus of ($0.23). Matterport, Inc. sees FY2022 revenue of $125-135 million, versus the consensus of $160.39 million.</p><p>QuantumScape (NYSE:QS)6.6% LOWER; reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11).</p><p>Informatica (NYSE:INFA)5.9% LOWER; reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $406.7 million versus the consensus estimate of $396.41 million. Informatica sees Q1 20122 revenue of $357-367 million, versus the consensus of $362.32 million. Informatica sees FY20122 revenue of $1.585-1.605 billion, versus the consensus of $1.5 billion.</p><p>Applied Materials (NASDAQ:AMAT)2.5% HIGHER; reported Q1 EPS of $1.89, $0.03 better than the analyst estimate of $1.86. Revenue for the quarter came in at $6.27 billion versus the consensus estimate of $6.17 billion. Applied Materials sees Q2 2022 EPS of $1.75-$2.05, versus the consensus of $1.94. Applied Materials sees Q2 2022 revenue of $6.35 billion, versus the consensus of $6.38 billion.</p><p>Cisco Systems (NASDAQ:CSCO)1.3% HIGHER; reported Q2 EPS of $0.84, $0.03 better than the analyst estimate of $0.81. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.65 billion. Cisco Systems sees Q3 2022 EPS of $0.85-$0.87, versus the consensus of $0.86. Revenue: 3% to 5% growth year over year; Cisco Systems sees FY2022 EPS of $3.41-$3.46, versus the consensus of $3.42. Revenue: 5.5% to 6.5% growth year over year</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Cisco,DoorDash,Fastly,AppLovin,Matterport and More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Cisco,DoorDash,Fastly,AppLovin,Matterport and More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-17 07:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+0216%3A+%28DASH%29+%28AMAT%29+%28CSCO%29+Higher%3B+%28FSLY%29+%28TXG%29+%28APP%29+Lower+%28more...%29/19635936.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:DoorDash (NYSE:DASH)27.1% HIGHER; reported Q4 EPS of ($0.45), $0.18 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.3 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+0216%3A+%28DASH%29+%28AMAT%29+%28CSCO%29+Higher%3B+%28FSLY%29+%28TXG%29+%28APP%29+Lower+%28more...%29/19635936.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QS":"Quantumscape Corp.","FSLY":"Fastly, Inc.","TXG":"10x Genomics, Inc.","MTTR":"Matterport, Inc.","INFA":"Informatica Inc.","AMAT":"应用材料","APP":"AppLovin Corporation","CSCO":"思科","DASH":"DoorDash, Inc."},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+0216%3A+%28DASH%29+%28AMAT%29+%28CSCO%29+Higher%3B+%28FSLY%29+%28TXG%29+%28APP%29+Lower+%28more...%29/19635936.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161878158","content_text":"After-Hours Stock Movers:DoorDash (NYSE:DASH)27.1% HIGHER; reported Q4 EPS of ($0.45), $0.18 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.28 billion. We expect Q1 Marketplace GOV to be in a range of $11.4 billion to $11.8 billion, with Q1 Adjusted EBITDA in a range of $0 million to $50 million. We expect 2022 Marketplace GOV to be in a range of $48 billion to $50 billion, with 2022 Adjusted EBITDA in a range of $0 million to $500 million.Fastly, Inc. (NYSE:FSLY)23.3% LOWER; reported Q4 EPS of ($0.10), $0.06 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $97.7 million versus the consensus estimate of $92.44 million. Fastly, Inc. sees Q1 2022 EPS of ($0.15)-($0.13), versus the consensus of ($0.13). Fastly, Inc. sees Q1 2022 revenue of $97-100 million, versus the consensus of $97.98 million. Fastly, Inc. sees FY2022 EPS of ($0.60)-($0.50), versus the consensus of ($0.48). Fastly, Inc. sees FY2022 revenue of $400-410 million, versus the consensus of $418.98 million.10x Genomics (NASDAQ:TXG)21.3% LOWER; reported Q4 EPS of ($0.16), $0.07 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $143.5 million versus the consensus estimate of $148.53 million. 10x Genomics sees FY2022 revenue of $600-630 million, versus the consensus of $679 million.AppLovin (NASDAQ:APP)17% LOWER; reported Q4 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $793 million versus the consensus estimate of $783.36 million. AppLovin sees FY2022 revenue of $3.55-3.85 billion, versus the consensus of $3.82 billion.Matterport, Inc. (NASDAQ:MTTR)10.1% LOWER; reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $27.1 million versus the consensus estimate of $25.13 million. Total subscribers increased 98% to 503,000 from year-ago period. Matterport, Inc. sees Q1 2022 EPS of ($0.13)-($0.15), versus the consensus of ($0.04). Matterport, Inc. sees Q1 2022 revenue of $25.5-27.5 million, versus the consensus of $31.85 million. Matterport, Inc. sees FY2022 EPS of ($0.47)-($0.52), versus the consensus of ($0.23). Matterport, Inc. sees FY2022 revenue of $125-135 million, versus the consensus of $160.39 million.QuantumScape (NYSE:QS)6.6% LOWER; reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11).Informatica (NYSE:INFA)5.9% LOWER; reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $406.7 million versus the consensus estimate of $396.41 million. Informatica sees Q1 20122 revenue of $357-367 million, versus the consensus of $362.32 million. Informatica sees FY20122 revenue of $1.585-1.605 billion, versus the consensus of $1.5 billion.Applied Materials (NASDAQ:AMAT)2.5% HIGHER; reported Q1 EPS of $1.89, $0.03 better than the analyst estimate of $1.86. Revenue for the quarter came in at $6.27 billion versus the consensus estimate of $6.17 billion. Applied Materials sees Q2 2022 EPS of $1.75-$2.05, versus the consensus of $1.94. Applied Materials sees Q2 2022 revenue of $6.35 billion, versus the consensus of $6.38 billion.Cisco Systems (NASDAQ:CSCO)1.3% HIGHER; reported Q2 EPS of $0.84, $0.03 better than the analyst estimate of $0.81. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.65 billion. Cisco Systems sees Q3 2022 EPS of $0.85-$0.87, versus the consensus of $0.86. Revenue: 3% to 5% growth year over year; Cisco Systems sees FY2022 EPS of $3.41-$3.46, versus the consensus of $3.42. Revenue: 5.5% to 6.5% growth year over year","news_type":1},"isVote":1,"tweetType":1,"viewCount":481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9092464839,"gmtCreate":1644715512150,"gmtModify":1676533955053,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"👍👍👍👍👍","listText":"👍👍👍👍👍","text":"👍👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9092464839","repostId":"2210409526","repostType":4,"repost":{"id":"2210409526","pubTimestamp":1644633920,"share":"https://ttm.financial/m/news/2210409526?lang=&edition=fundamental","pubTime":"2022-02-12 10:45","market":"us","language":"en","title":"China Approves Use of Pfizer's COVID Drug Paxlovid","url":"https://stock-news.laohu8.com/highlight/detail?id=2210409526","media":"Reuters","summary":"BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditi","content":"<html><head></head><body><p>BEIJING, Feb 12 (Reuters) - China&#39;s medical products regulator said on Saturday it has given conditional approval for Pfizer&#39;s COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.</p><p>The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.</p><p>It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment. </p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Approves Use of Pfizer's COVID Drug Paxlovid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Approves Use of Pfizer's COVID Drug Paxlovid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-12 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus ...</p>\n\n<a href=\"https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓","BK4007":"制药","BK4124":"机动车零配件与设备","PFE":"辉瑞"},"source_url":"https://finance.yahoo.com/news/1-china-approves-pfizers-covid-024520927.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2210409526","content_text":"BEIJING, Feb 12 (Reuters) - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 treatment Paxlovid, making it the first oral anti-coronavirus pill approved in the country to treat the disease.The National Medical Products Administration said Paxlovid has obtained conditional approval to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the drug needed to be conducted and submitted to the authority, it said.It is not immediately clear if China is already in talks with Pfizer to procure the pill. Pfizer did not reply to a Reuters request for comment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863140307,"gmtCreate":1632367382309,"gmtModify":1676530764975,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"??????","listText":"??????","text":"??????","images":[{"img":"https://static.tigerbbs.com/b70590264c4d046cc0eaecdd6fcc73a9","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863140307","isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869636367,"gmtCreate":1632278239559,"gmtModify":1676530741874,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"?????","listText":"?????","text":"?????","images":[{"img":"https://static.tigerbbs.com/e64d55b0d66b0f91e5a69e71b3089278","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869636367","isVote":1,"tweetType":1,"viewCount":284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":860578097,"gmtCreate":1632192537019,"gmtModify":1676530722248,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"?????","listText":"?????","text":"?????","images":[{"img":"https://static.tigerbbs.com/a25587dcdf42d19e669c849b1e1706b8","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/860578097","isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":887720757,"gmtCreate":1632100993479,"gmtModify":1676530700376,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"?????","listText":"?????","text":"?????","images":[{"img":"https://static.tigerbbs.com/f56c17c71db35505d37f4feecfce858b","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887720757","isVote":1,"tweetType":1,"viewCount":120,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":888583058,"gmtCreate":1631507261674,"gmtModify":1676530561136,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"??????","listText":"??????","text":"??????","images":[{"img":"https://static.tigerbbs.com/ec71d7e2531a12d2233940d8b81fcfa1","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/888583058","isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":881717457,"gmtCreate":1631405605079,"gmtModify":1676530540780,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"?????","listText":"?????","text":"?????","images":[{"img":"https://static.tigerbbs.com/b776e628d1ff0686e9df4d583dd2e947","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881717457","isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":881652783,"gmtCreate":1631334390742,"gmtModify":1676530531597,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"????","listText":"????","text":"????","images":[{"img":"https://static.tigerbbs.com/53b9aefc7a6fe1cd78f6a7ff9b2ea7f3","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/881652783","isVote":1,"tweetType":1,"viewCount":202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":883285370,"gmtCreate":1631244480590,"gmtModify":1676530507461,"author":{"id":"3586770547015924","authorId":"3586770547015924","name":"KkKkkkk","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586770547015924","authorIdStr":"3586770547015924"},"themes":[],"htmlText":"????","listText":"????","text":"????","images":[{"img":"https://static.tigerbbs.com/3b9caf3055cf973f065db14e9baca625","width":"1080","height":"3255"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883285370","isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}